Want to see GB:TSTL full AI Analyst Report?
Tristel (TSTL) AI Stock Analysis
Top Page
Tristel
(LSE:TSTL)
The score is driven primarily by strong financial performance (high margins, improving profitability, low leverage, and robust cash conversion) and a very constructive earnings call with reaffirmed long-term growth and margin commitments. Offsetting factors are only moderate technicals (near-term weakness versus shorter moving averages and a low RSI) and a somewhat premium valuation (P/E ~26) despite a supportive ~3.48% dividend yield.
Tristel (TSTL) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 194.70M
- Dividend Yield
- 3.51%
- Average Volume (3M)
- 104.11K
- Price to Earnings (P/E)
- 24.3
- Beta (1Y)
- 0.56
- Revenue Growth
- 10.02%
- EPS Growth
- 19.83%
- Country
- UK
- Employees
- 282
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Tristel Business Overview & Revenue Model
Company Description
Tristel plc is a company specializing in the creation, production, and global distribution of products designed to prevent infections, serving both its home market in the UK and international clients. Its operations are structured around three core d...
How the Company Makes Money
Tristel makes money primarily by selling decontamination consumables and related solutions to healthcare providers and other regulated users. Its core revenue stream is the ongoing sale of proprietary chlorine dioxide–based disinfectant products (e.g...
Tristel Earnings Call Summary
The call was strongly optimistic. The company reported record revenue, double-digit growth, higher adjusted profit before tax, a 31% adjusted EBITDA margin, strong cash generation, no debt and a growing dividend. Management also highlighted substantial U.S. pipelines, new product launches, digital platform adoption, clinical evidence and significant market opportunities. The main negatives were legacy product declines, isolated competitive and tender-related challenges, higher tax expense, a one-off impairment and employee-share-scheme dilution. Overall, the highlights significantly outweighed the lowlights.
Q4-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management said results remain in line with expectations and the business is firmly on track to meet its financial targets, with a commitment out to 2030 of revenue growth that's not less than double digit on an annual basis, an EBITDA margin that exceeds 25% and a progressive year-on-year dividend growth policy. Priorities include accelerating U.S. growth, increasing commercial, clinical and R&D investment, expanding existing and new markets, launching Unifoam in January in a first phase market, and targeting an opportunity somewhere in the magnitude of GBP 40 million from bringing direct markets up to the median distribution, with further opportunity up to GBP 60 million from internal benchmarks.
Tristel Financial Statement Overview
Summary
Strong and improving profitability with very high gross margins (~77%–82%) and expanding EBIT margin (~15% in 2023 to ~22% in 2026). Cash generation is high-quality with operating cash flow consistently exceeding earnings and solid free-cash-flow conversion (~71%–94%). Balance sheet leverage is low with improving ROE (to ~22% in 2026), though historical profitability volatility (notably 2022) is the main watch item.
Income Statement
86Very PositiveBalance Sheet
82Very PositiveCash Flow
88Very Positive| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 51.12M | 51.12M | 46.46M | 41.93M | 36.01M | 31.12M |
| Gross Profit | 39.30M | 39.30M | 37.94M | 33.58M | 29.18M | 24.66M |
| EBITDA | 14.25M | 14.25M | 11.47M | 10.01M | 7.90M | 4.46M |
| Net Income | 7.98M | 7.98M | 6.64M | 6.49M | 4.46M | 987.00K |
Balance Sheet | ||||||
| Total Assets | 48.27M | 48.27M | 45.33M | 44.11M | 41.37M | 38.74M |
| Cash, Cash Equivalents and Short-Term Investments | 16.00M | 16.00M | 12.84M | 11.79M | 9.54M | 8.88M |
| Total Debt | 5.86M | 5.86M | 5.88M | 5.86M | 5.18M | 5.81M |
| Total Liabilities | 12.55M | 12.55M | 12.34M | 11.70M | 10.68M | 9.75M |
| Stockholders Equity | 35.72M | 35.72M | 32.99M | 32.41M | 30.68M | 28.98M |
Cash Flow | ||||||
| Free Cash Flow | 10.82M | 10.82M | 9.46M | 10.06M | 6.07M | 4.35M |
| Operating Cash Flow | 11.50M | 11.50M | 10.32M | 10.89M | 8.49M | 5.55M |
| Investing Cash Flow | 1.94M | 1.94M | -254.00K | -5.08M | -4.84M | -1.20M |
| Financing Cash Flow | -7.18M | -7.18M | -7.30M | -6.57M | -5.44M | -3.62M |
Tristel Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:TSTL, the sentiment is Negative. The current price of 405.00 is below the 20-day moving average (MA) of 415.80, below the 50-day MA of 411.33, and above the 200-day MA of 398.89, indicating a neutral trend. The MACD of -2.78 indicates Positive momentum. The RSI at 45.00 is Neutral, neither overbought nor oversold. The STOCH value of 46.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:TSTL.
Tristel Peers Comparison
Overall Rating
- GB:TSTL78Outperform
GB:SN72Outperform
GB:CTEC71Outperform
GB:AMS67Neutral
GB:CVSG55Neutral
GB:SUN43.6Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:TSTL | 78Outperform | GBP 194.70M | 24.28 | 23.05% | 3.51% | 10.02% | 19.83% |
| GB:SN | 72Outperform | GBP 9.27B | 19.52 | 12.25% | 2.66% | 2.17% | 27.33% |
| GB:CTEC | 71Outperform | GBP 4.67B | 51.60 | 8.40% | 2.28% | 1.94% | -43.71% |
| GB:AMS | 67Neutral | GBP 611.34M | 166.18 | 1.44% | 1.66% | 6.05% | -60.00% |
| GB:CVSG | 55Neutral | GBP 885.45M | 53.08 | 5.91% | 0.64% | 5.88% | -9.18% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:SUN | 44Neutral | GBP 3.73M | -4.00 | -15.47% | ― | -3.68% | 20.00% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:TSTL | Tristel plc | 405.00 | 58.67 | 16.94% | |
| GB:AMS | Advanced Medical Solutions | 282.50 | 67.49 | 31.39% | |
| GB:CTEC | ConvaTec Group plc | 244.40 | 11.17 | 4.79% | |
| GB:CVSG | CVS Group plc | 1327.00 | 63.79 | 5.05% | |
| GB:SUN | Surgical Innovations Group Plc | 0.40 | -0.18 | -31.03% | |
| GB:SN | Smith & Nephew (UK) | 1107.50 | -251.88 | -18.53% |
Tristel Corporate Events
Tristel lifts profits and dividend as U.S. growth and digital push gather pace
PositiveHospital disinfectant manufacturer Tristel reported another year of double-digit growth, with revenue up 10% to £51.1m and adjusted pre-tax profit rising 15% to £11.7m. The group maintained an 82% gross margin, lifted its full-year dividend...
Tristel Sets October Date for 2026 Results and Investor Briefings
PositiveTristel plc, the AIM-listed infection prevention specialist, will publish its financial results for the year ended 30 June 2026 on 19 October 2026. The company plans to use the occasion to engage closely with analysts and investors through both onlin...
Tristel Updates Share Capital After Employee Option Exercise
NeutralTristel plc has issued and allotted 51,000 new ordinary shares following the exercise of share options by employees, with the shares expected to be admitted to trading on AIM on 14 August 2026. After admission, the company’s total ordinary shar...
Tristel Issues New Shares After Employee Option Exercise, Lifts Voting Rights Total
NeutralTristel plc, the AIM-listed infection prevention specialist using proprietary chlorine dioxide technology, supplies hospitals worldwide with manual medical device decontamination and sporicidal surface disinfection products, and aims for double-digit...
Tristel launches premium paid tier of 3T compliance platform
PositiveTristel plc, a specialist in infection prevention solutions for hospitals, has expanded its offering with the commercial launch of 3T Pro, a premium tier of its 3T digital compliance platform. The company, known for chlorine dioxide-based medical dev...
Tristel posts double‑digit growth and boosts cash ahead of new CEO arrival
PositiveTristel has reported another year of strong trading, with revenues for the year to 30 June 2026 rising 10% to £51.1m and adjusted profit before tax expected to grow 14% to at least £11.5m, slightly ahead of market forecasts. The companyR...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 20, 2026